European Journal of Vascular & Endovascular Surgery
Volume 35, Issue 2 , Pages 145-152 , February 2008

Recombinant Activated Factor VII: A Solution to Refractory Haemorrhage in Vascular Surgery?

  • O.J. Warren

      Affiliations

    • Department of BioSurgery and Surgical Technology, Imperial College, London, United Kingdom
    • Corresponding Author InformationCorresponding author. Mr. O. Warren BSc (Hons) MRCS, Department of BioSurgery and Surgical Technology, Imperial College, London, 10th Floor QEQM Building, St. Mary's Hospital, London, W2 1NY, United Kingdom.
    • ,
  • E.M.H. Alcock

      Affiliations

    • Department of BioSurgery and Surgical Technology, Imperial College, London, United Kingdom
    • ,
  • A.M.T.L. Choong

      Affiliations

    • Department of BioSurgery and Surgical Technology, Imperial College, London, United Kingdom
    • Regional Vascular Unit, St. Mary's Hospital, London, United Kingdom
    • ,
  • D.R. Leff

      Affiliations

    • Department of BioSurgery and Surgical Technology, Imperial College, London, United Kingdom
    • ,
  • I. Van Herzeele

      Affiliations

    • Department of BioSurgery and Surgical Technology, Imperial College, London, United Kingdom
    • Regional Vascular Unit, St. Mary's Hospital, London, United Kingdom
    • ,
  • A.W. Darzi

      Affiliations

    • Department of BioSurgery and Surgical Technology, Imperial College, London, United Kingdom
    • ,
  • T. Athanasiou

      Affiliations

    • Department of BioSurgery and Surgical Technology, Imperial College, London, United Kingdom
    • ,
  • N.J.W. Cheshire

      Affiliations

    • Department of BioSurgery and Surgical Technology, Imperial College, London, United Kingdom
    • Regional Vascular Unit, St. Mary's Hospital, London, United Kingdom

,Accepted 27 August 2007.

References 

  1. Cohen JR, Angus L, Asher A, Chang JB, Wise L. Disseminated intravascular coagulation as a result of supraceliac clamping: implications for thoracoabdominal aneurysm repair. Ann Vasc Surg. 1987;1(5):552–557
  2. Jelenska MM, Szmidt J, Bojakowski K, Grzela T, Palester-Chlebowczyk M. Compensated activation of coagulation in patients with abdominal aortic aneurysm: effects of heparin treatment prior to elective surgery. Thromb Haemost. 2004;92(5):997–1002
  3. Halpern VJ, Kline RG, D'Angelo AJ, Cohen JR. Factors that affect the survival rate of patients with ruptured abdominal aortic aneurysms. J Vasc Surg. 1997;26(6):939–945[discussion 945–938]
  4. Sultan S, Manecksha R, O'Sullivan J, Hynes N, Quill D, Courtney D. Survival of ruptured abdominal aortic aneurysms in the west of Ireland: do prognostic indicators of outcome exist?. Vasc Endovascular Surg. 2004;38(1):43–49
  5. Sedrakyan A, Wu A, Sedrakyan G, Diener-West M, Tranquilli M, Elefteriades J. Aprotinin use in thoracic aortic surgery: safety and outcomes. J Thorac Cardiovasc Surg. 2006;132(4):909–917
  6. Huber TS, Carlton LC, Irwin PB, Flug RR, Harward TR, Flynn TC, et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction. J Surg Res. 1997;67(1):14–20
  7. Milne AA, Drummond GB, Paterson DA, Murphy WG, Ruckley CV. Disseminated intravascular coagulation after aortic aneurysm repair, intraoperative salvage autotransfusion, and aprotinin. Lancet. 1994;344(8920):470–471
  8. Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;2(8621):1193
  9. Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost. 2000;26(4):363–366
  10. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(3):293–298
  11. Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007;83(2):707–714
  12. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361(9353):201–205
  13. Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth. 2005;94(5):586–591
  14. Tawfick WA, Tawfik S, Hynes N, Mahendran B, Sultan S. Critical bleeding in vascular surgery: expanding the indication of recombinant activated factor VII. Vascular. 2006;14(1):32–37
  15. Cheng CA, Ho AM. Use of recombinant activated factor VII after axillofemoral bypass grafting. Anaesth Intensive Care. 2006;34(3):375–378
  16. Raux M, Chiche L, Vanhille E, Riou B. Recombinant activated factor vii to control massive post operative bleeding after septic aortobifemoral grafting. Eur J Anaesthesiol. 2005;22(10):805–807
  17. Liem AK, Biesma DH, Ernst SM, Schepens AA. Recombinant activated factor VII for false aneurysms in patients with normal haemostatic mechanisms. Thromb Haemost. 1999;82(1):150–151
  18. Wahlgren CM, Swedenborg J. The use of recombinant activated factor VII to control bleeding during repair of a suprarenal abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2003;26(2):221–222
  19. Benharash P, Bongard F, Putnam B. Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients. Am Surg. 2005;71(9):776–780
  20. Laffan M, O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy D, Smith OP. Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagul Fibrinolysis. 2003;14(1):S35–S38
  21. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion. 2003;43(12):1711–1716
  22. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol. 2002;22(4):539–548
  23. Jude B, Zawadzki C, Susen S, Corseaux D. Relevance of tissue factor in cardiovascular disease. Arch Mal Coeur Vaiss. 2005;98(6):667–671
  24. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349(9054):769–771
  25. Nijziel M, van Oerle R, van 't Veer C, van Pampus E, Lindhout T, Hamulyak K. Tissue factor activity in human monocytes is regulated by plasma: implications for the high and low responder phenomenon. Br J Haematol. 2001;112(1):98–104
  26. Maugeri N, Brambilla M, Camera M, Carbone A, Tremoli E, Donati MB, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost. 2006;4(6):1323–1330
  27. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost. 2006;32(1):11–23
  28. Khan MM, Hattori T, Niewiarowski S, Edmunds LH, Colman RW. Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII. Thromb Haemost. 2006;95(3):462–468
  29. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation. 2002;106(19):2442–2447
  30. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA. 1999;96(5):2311–2315
  31. Santucci RA, Erlich J, Labriola J, Wilson M, Kao KJ, Kickler TS, et al. Measurement of tissue factor activity in whole blood. Thromb Haemost. 2000;83(3):445–454
  32. Butenas S, Mann KG. Active tissue factor in blood?. Nat Med. 2004;10(11):1155–1156[author reply 1156]
  33. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol. 2003;1(2):112–119
  34. Butenas S, Brummel KE, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in “acquired” hemophilia. Arterioscler Thromb Vasc Biol. 2003;23(1):123–129
  35. ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993;92(3):1207–1212
  36. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost. 2003;1(6):1138–1139
  37. Bom VJ, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J. 1990;265(2):327–336
  38. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99(3):542–547
  39. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood. 1994;83(1):38–42
  40. Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost. 2004;91(5):977–985
  41. Manning BJ, Hynes N, Courtney DF, Sultan S. Recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery. Eur J Vasc Endovasc Surg. 2005;30(5):525–527
  42. Pugh RJ, Wenstone R, Martlew VJ, Marx G. Use of recombinant factor VIIa for major haemorrhage. Eur J Anaesthesiol. 2005;22(7):548–550
  43. Aggarwal A, Malkovska V, Catlett JP, Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb J. 2004;2(1):9
  44. Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis. 2003;14(8):713–717
  45. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005;80(1):66–71
  46. Khan AZ, Parry JM, Crowley WF, McAllen K, Davis AT, Bonnell BW, et al. Recombinant factor VIIa for the treatment of severe postoperative and traumatic hemorrhage. Am J Surg. 2005;189(3):331–334
  47. Bishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg. 2006;81(3):875–879
  48. Clark AD, Gordon WC, Walker ID, Tait RC. ‘Last-ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang. 2004;86(2):120–124
  49. Edmunds LH, Colman RW. Thrombin during cardiopulmonary bypass. Ann Thorac Surg. 2006;82(6):2315–2322
  50. Naik VN, Mazer CD, Latter DA, Teitel JM, Hare GM. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth. 2003;50(6):599–602
  51. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354(9193):1879
  52. Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion. 2006;46(6):919–933
  53. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59(1):8–15[discussion 15–18]
  54. Shander A, Goodnough LT, Ratko T, Matuszewski KA, Cohn S, Diringer M, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. Pharma Ther. 2005;30:644–658
  55. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44(9):1325–1331
  56. Roberts HR. Recombinant factor VIIa: a general hemostatic agent?. Yes. J Thromb Haemost. 2004;2(10):1691–1694
  57. Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al. How to formulate research recommendations. BMJ. 2006;333(7572):804–806

PII: S1078-5884(07)00557-6

doi: 10.1016/j.ejvs.2007.08.018

European Journal of Vascular & Endovascular Surgery
Volume 35, Issue 2 , Pages 145-152 , February 2008

Article Tools

* Image Usage & Resolution